Methotrexate and biologics linked to higher zoster risk in psoriasisMarch 22, 2015Psoriatic ArthritisSpondyloarthropathies
Secukinumab beat ustekinumab for psoriasis, with difference by week fourMarch 21, 2015SpondyloarthropathiesPsoriatic Arthritis
Brodalumab achieved primary endpoints for moderate to severe psoriasis at 52 weeksMarch 21, 2015SpondyloarthropathiesPsoriatic Arthritis
Halting biologics before surgery tied to flares in psoriasis, psoriatic arthritisMarch 13, 2015Psoriatic ArthritisSpondyloarthropathies
Interleukin-23 inhibition with tildrakizumab achieves significant psoriasis improvementsMarch 9, 2015Psoriatic ArthritisSpondyloarthropathies
Infliximab most common cause of drug-induced liver injuryMarch 1, 2015Rheumatoid ArthritisSpondyloarthropathiesPsoriatic Arthritis
New psoriasis drugs offer treatment advantagesFebruary 27, 2015SpondyloarthropathiesPsoriatic Arthritis
Data suggest link between tonsillectomy, psoriasis improvementFebruary 25, 2015SpondyloarthropathiesPsoriatic Arthritis
Ixekizumab improves lesions in patients with chronic plaque psoriasis after 20 weeksFebruary 24, 2015Psoriatic ArthritisSpondyloarthropathies
Unique psoriatic arthritis genetic risk loci discoveredFebruary 6, 2015SpondyloarthropathiesPsoriatic Arthritis
Methotrexate coverage woesFebruary 3, 2015Ankylosing spondylitisPsoriatic ArthritisSpondyloarthropathiesRheumatoid Arthritis
Most cost-effective psoriasis treatment: methotrexateJanuary 30, 2015SpondyloarthropathiesPsoriatic Arthritis
Survey: Psoriasis/psoriatic arthritis undertreatedJanuary 30, 2015SpondyloarthropathiesPsoriatic Arthritis
Joint mechanical stress: A psoriatic arthritis trigger in genetically susceptible individuals?January 29, 2015SpondyloarthropathiesPsoriatic Arthritis
